Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | ACHE | P22303 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | BPTF | Q12830 | 1/20 | 0.54 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.44 |
| ▸ | APAF1 | O14727 | 1/20 | 0.43 |
| ▸ | NSD2 | O96028 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HRH2 | P25021 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29661474 | 1.00 | KDM4E (0.57) | KDM4EACHEMEN1MAPK1KMT2A | |
| SCHEMBL3563842 | 0.95 | KDM4E (0.63) | KDM4EACHEMEN1MAPK1KMT2A | |
| Ethylene SCHEMBL8636905 | 0.91 | KDM4E (0.59) | KDM4EACHEMEN1MAPK1KMT2A | |
| SCHEMBL21963098 | 0.78 | ACHE (0.56) | KDM4EACHEMEN1MAPK1KMT2A | |
| SCHEMBL9267023 | 0.77 | ACHE (0.50) | KDM4EACHEMEN1MAPK1KMT2A | |
| SCHEMBL13394086 | 0.77 | KDM4E (0.53) | KDM4EACHEMEN1MAPK1KMT2A | |
| SCHEMBL2922186 | 0.77 | KDM4E (0.53) | KDM4EACHEMEN1MAPK1KMT2A | |
| SCHEMBL11563224 | 0.77 | ACHE (0.50) | KDM4EACHEMEN1MAPK1KMT2A | |
| SCHEMBL9886276 | 0.77 | KDM4E (0.92) | KDM4EACHEMEN1MAPK1KMT2A | |
| SCHEMBL4195401 | 0.76 | KDM4E (0.38) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3717472-A1 | PYRIMIDINE DERIVATIVES | H. Hoffnabb-La Roche Ag (CH) | 2020-10-07 | — | — | EP | claimed |
| WO-2019101984-A1 | PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2019-05-31 | — | — | WO | claimed |
| EP-3717472-A1 | PYRIMIDINE DERIVATIVES | H. Hoffnabb-La Roche Ag (CH) | 2020-10-07 | — | — | EP | disclosed |
| WO-2019101984-A1 | PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2019-05-31 | — | — | WO | disclosed |
| WO-2013019966-A1 | AROMATIC BYCYCLIC DERIVATIVES AS CXCR4 RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-02-07 | — | — | WO | disclosed |
| US-20120028994-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2012-02-02 | — | — | US | disclosed |
| US-20110212937-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-01 | — | — | US | disclosed |
| WO-2011014535-A1 | COMPOUNDS FOR THE REDUCTION OF β-AMYLOID PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-03 | — | — | WO | disclosed |
| US-7820648-B2 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC (US) | 2010-10-26 | — | — | US | disclosed |
| US-20080234303-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC | 2008-09-25 | — | — | US | disclosed |
| EP-0530579-B1 | Condensed pyrimidine derivatives antitumor agents | EISAI CO LTD (JP) | 1998-11-11 | — | — | EP | disclosed |
| US-5554615-A | ANTITUMOR | EISAI CO., LTD. (JP) | 1996-09-10 | — | — | US | disclosed |
| EP-0530579-A1 | Condensed pyrimidine derivatives antitumor agents | Eisai Co., Ltd. (JP) | 1993-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212937-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | KDM4E 4438/4885ACHE 16/4885MEN1 3911/4885 |
| US-20080234303-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | CCNB1, TYMS, CCNA1 | KDM4E 2265/4885ACHE 4829/4885MEN1 2058/4885 |
| US-20120028994-A1 | COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION | APP, BACE1, IAPP | KDM4E 4438/4885ACHE 16/4885MEN1 3911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.